Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26

Rhea-AI Summary

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) will host its first R&D Day on September 26, 2022, in New York City. CEO Simon Allen, along with senior executives including Founder Dr. Joseph Lawler and CSO Dr. Ken Cundy, will present updates on the company's progress, particularly on the Phase 2 study of product candidate ANEB-001. This candidate aims to address acute cannabinoid intoxication. Institutional investors and analysts are invited to register via email as seating is limited.

AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), will host its inaugural R&D Day on Monday, September 26, 2022, from approximately 10:00 a.m. to 12:30 p.m. (ET) in Midtown, New York City.

Anebulo’s CEO, Simon Allen will be joined by Founder Dr. Joseph Lawler, CSO Dr. Ken Cundy and other senior executives to discuss the company’s vision, progress update on Anebulo’s ongoing Phase 2 proof-of-concept study related to ANEB-001, commercialization/partnership strategy, and target financial model. The event will include a question-and-answer session following presentations by Management.

Institutional investors and financial analysts are invited to attend and can register via email at AnebuloIR@mww.com. For additional information, please contact Samantha Alphonso at salphonso@mww.com or (212) 827-3746 as space is limited.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse disorder. Its lead product candidate, ANEB-001, is currently in a Phase 2 clinical trial (www.clinicaltrials.gov/ct2/show/NCT05282797) to evaluate its utility in reversing the negative effects of acute cannabinoid intoxication within one hour of administration. This trial is being run in the Netherlands by the Centre for Human Drug Research (CHDR). ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, along with terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Anebulo and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including risks attendant to developing, testing and commercializing the company’s product candidates, and those described in Anebulo’s most recent annual report on Form 10-K and in other periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Anebulo undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005835/en/

Anebulo Pharmaceuticals, Inc.

Scott Anderson

Head of Investor Relations and Public Relations

(858) 229-7063

scott@anebulo.com

Rex Merchant

Chief Financial Officer

(512) 598-0931

IR@anebulo.com

Source: Anebulo Pharmaceuticals, Inc.

FAQ

What is Anebulo Pharmaceuticals planning for September 26, 2022?

Anebulo Pharmaceuticals will host its inaugural R&D Day in New York City.

Who will present at Anebulo's R&D Day?

CEO Simon Allen, Founder Dr. Joseph Lawler, CSO Dr. Ken Cundy, and other executives will present.

What is the main focus of the R&D Day conducted by Anebulo Pharmaceuticals?

The focus will be on updates regarding the Phase 2 study of ANEB-001.

What is ANEB-001 used for?

ANEB-001 is being developed to reverse the effects of acute cannabinoid intoxication.

How can investors attend Anebulo's R&D Day?

Institutional investors can register via Anebulo's investor relations email.